Oncotarget 2015-06-10

The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs.

Ximena Bonilla, El-Habib Dakir, Faustino Mollinedo, Consuelo Gajate

Index: Int. J. Neuropsychopharmacol. 17(8) , 1269-82, (2014)

Full Text: HTML

Abstract

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a natural hallucinogen component of Ayahuasca, an Amazonian beverage traditionally used for ritual, religious and healing purposes that is being increasingly used for recreational purposes in US and Europe. 5MeO-DMT is of potential interest for schizophrenia research owing to its hallucinogenic properties. Two other psychotomimetic agents, phencyclidine and 2,5-dimethoxy-4-iodo-phenylisopropylamine (DOI), markedly disrupt neuronal activity and reduce the power of low frequency cortical oscillations (<4 Hz, LFCO) in rodent medial prefrontal cortex (mPFC). Here we examined the effect of 5-MeO-DMT on cortical function and its potential reversal by antipsychotic drugs. Moreover, regional brain activity was assessed by blood-oxygen level dependent (BOLD) functional magnetic resonance imaging (fMRI). 5-MeO-DMT disrupted mPFC activity, increasing and decreasing the discharge of 51 and 35% of the recorded pyramidal neurons, and reducing (-31%) the power of LFCO. The latter effect depended on 5-HT1A and 5-HT2A receptor activation and was reversed by haloperidol, clozapine, risperidone, and the mGlu2/3 agonist LY379268. Likewise, 5-MeO-DMT decreased BOLD responses in visual cortex (V1) and mPFC. The disruption of cortical activity induced by 5-MeO-DMT resembles that produced by phencyclidine and DOI. This, together with the reversal by antipsychotic drugs, suggests that the observed cortical alterations are related to the psychotomimetic action of 5-MeO-DMT. Overall, the present model may help to understand the neurobiological basis of hallucinations and to identify new targets in antipsychotic drug development.


Related Compounds

Related Articles:

Nest building is impaired in the Ts65Dn mouse model of Down syndrome and rescued by blocking 5HT2a receptors.

2014-12-01

[Neurobiol. Learn. Mem. 116 , 162-71, (2014)]

Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.

2014-09-01

[J. Pharmacol. Exp. Ther. 350(3) , 589-604, (2014)]

Utility of cerebrospinal fluid drug concentration as a surrogate for unbound brain concentration in nonhuman primates.

2014-01-01

[Drug Metab. Pharmacokinet. 29(5) , 419-26, (2014)]

A validated high-throughput UHPLC-MS/MS assay for accurate determination of rivaroxaban in plasma sample.

2015-01-01

[J. Thromb. Thrombolysis 39(1) , 79-88, (2015)]

Simple and sensitive screening and quantitative determination of 88 psychoactive drugs and their metabolites in blood through LC–MS/MS: Application on postmortem samples

2014-11-01

[J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 970 , 1-7, (2014)]

More Articles...